Monday, May 05, 2025 12:09:34 AM
Gro,
Thanks for reposting your keen insights 😶
It sounds like you’re spreading rumors and disinformation. I believe you’re referring to Gilead’s Yescarta and your ‘facts’ are a little mixed up…
“As of early 2023, NICE has approved Yescarta (axicabtagene ciloleucel) for routine use in the NHS. After a series of reviews and negotiations, NICE endorsed Yescarta for adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). The approval was based on the evidence of its effectiveness in prolonging survival compared to existing therapies.
This approval marked a shift from earlier hesitations due to concerns about high costs and uncertainty about long-term benefits. The conditional use through the Cancer Drugs Fund helped collect additional evidence, leading to the final NICE endorsement.”
https://pmlive.com/pharma_news/gileads_car-t_cell_therapy_recommended_by_nice_for_lymphoma_1485970/
NICE DCVax-L
Thanks for reposting your keen insights 😶
It sounds like you’re spreading rumors and disinformation. I believe you’re referring to Gilead’s Yescarta and your ‘facts’ are a little mixed up…
“As of early 2023, NICE has approved Yescarta (axicabtagene ciloleucel) for routine use in the NHS. After a series of reviews and negotiations, NICE endorsed Yescarta for adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). The approval was based on the evidence of its effectiveness in prolonging survival compared to existing therapies.
This approval marked a shift from earlier hesitations due to concerns about high costs and uncertainty about long-term benefits. The conditional use through the Cancer Drugs Fund helped collect additional evidence, leading to the final NICE endorsement.”
https://pmlive.com/pharma_news/gileads_car-t_cell_therapy_recommended_by_nice_for_lymphoma_1485970/
NICE DCVax-L
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
